The stock appears overpriced with its high beta causing amplified price movements. Its optimistic future growth seems already factored into the current share price, making it potentially not the best time to buy as it has outpaced its industry peers.
Despite lower forecasted growth, Life Time Group's P/S ratio is on par with industry peers, hinting investor loyalty. However, alignment of P/S ratio with the growth outlook could result in disappointment. Weak revenue outlook puts the share price at risk requiring positive change to justify P/S ratio.
Life Time股票討論區
資產負債表上商譽及其他無形資產14.1億,佔淨資產21.24億的2/3。長期借款18.1億,佔淨資產的85%,槓桿率不算低。
資產的流動性很差,66.3億總資產中僅有1.3億流動資產,目前流動比率降到了0.3,風險非常大,目前缺乏投資價值。
專欄Today's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA生物科學(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...
暫無評論